Pricing Log in Create free account

Carisma Therapeutics Inc. (CARM) vs Karyopharm Therapeutics Inc. (KPTI)

Carisma Therapeutics Inc. and Karyopharm Therapeutics Inc. are both Biotechnology companies. Carisma Therapeutics Inc. is the larger, with a market value of $1.5M against $1.4M — 1.1× the size. Carisma Therapeutics Inc. grew revenue faster over the last twelve months: 170.5% against 6.81%. Carisma Therapeutics Inc. has the higher net margin (14.4% vs −153.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Carisma Therapeutics Inc. leads on 12 and Karyopharm Therapeutics Inc. on 3.

Valuation

Metric CARM KPTI Biotechnology median
P/E n/m n/m 10.60
P/S n/m 0.01 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales (0.05) 1.27 9.02
Earnings yield 0.00% (25,680.00%) (32.88%)
Free cash flow yield 0.00% (4,526.16%) (23.13%)

Profitability

Metric CARM KPTI Biotechnology median
Gross margin 100.00% 95.89% 68.51%
Operating margin 19.36% (56.17%) 0.00%
Net margin 14.36% (153.28%) 0.00%
Free cash flow margin (38.79%) (44.57%) 0.00%
Return on equity (134.11%) 78.98% (51.96%)
Return on assets 33.09% (207.90%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CARM KPTI Biotechnology median
Revenue growth (TTM) 170.48% 6.81% 6.76%
EPS growth (last fiscal year) 43.68% (28.07%) 29.88%
Revenue growth, 5-year CAGR 115.24% 6.21% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CARM KPTI Biotechnology median
Debt to equity 0.00 (0.76) 0.00
Current ratio 0.86 0.79 4.97
Net debt to EBITDA 0.30 (2.03) 1.01

Dividend

Metric CARM KPTI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CARM KPTI Biotechnology median
Market cap 1.52m 1.36m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack